SavedAdd your journal

Journals / Türk Göğüs Kalp Damar Cerrahisi Dergisi / 2009 / Cilt: 17 - Sayı: 2

Comparison of ADP-and collagen-induced platelet aggregation responses between patients with Buerger's disease and healthy individuals

Buerger hastalığında ADP ve kollajen ile tetiklenmiş trombosit agregasyonu yanıtlarının sağlıklı kişilerle karşılaştırılması

Ahmet Kürşat BOZKURT
Mine Yılmaz DEMİRBAŞ
Muhterem GÜLSEVER
Pages
106–109
Publication Date
2022-09-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Collageninduced response was 90.5±10.0% in the patient group, and %88.5±2.3% in the control group (p>0.05).Conclusion: Our findings suggest that patients with Buerger's disease do not have a tendency to platelet aggregation.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: We investigated platelet aggregation levels triggered by adenosine diphosphate (ADP) and collagen in patients with Buerger's disease who were not on antiplatelet or hemorheologic treatment.Methods: We measured ADP- and collagen-induced platelet aggregation responses in 10 patients with Fontaine IIIIV Buerger's disease without a history of antiaggregant or hemorheologic therapies and in 10 male healthy individuals under the age of 50 years (control group).
📊
Key Findings & Data:Measurements were made on a Chrono-log platelet aggregometer using ADP and collagen Chrono-log kits.Results: The mean platelet aggregation responses triggered by ADP were 78.7±9.7% and 81.5±3.5% in the patient and control groups, respectively (p>0.05).
💡
Conclusion & Impact:Collageninduced response was 90.5±10.0% in the patient group, and %88.5±2.3% in the control group (p>0.05).Conclusion: Our findings suggest that patients with Buerger's disease do not have a tendency to platelet aggregation.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: We investigated platelet aggregation levels triggered by adenosine diphosphate (ADP) and collagen in patients with Buerger's disease who were not on antiplatelet or hemorheologic treatment.Methods: We measured ADP- and collagen-induced platelet aggregation responses in 10 patients with Fontaine IIIIV Buerger's disease without a history of antiaggregant or hemorheologic therapies and in 10 male healthy individuals under the age of 50 years (control group). Measurements were made on a Chrono-log platelet aggregometer using ADP and collagen Chrono-log kits.Results: The mean platelet aggregation responses triggered by ADP were 78.7±9.7% and 81.5±3.5% in the patient and control groups, respectively (p>0.05). Collageninduced response was 90.5±10.0% in the patient group, and %88.5±2.3% in the control group (p>0.05).Conclusion: Our findings suggest that patients with Buerger's disease do not have a tendency to platelet aggregation.

Özet

Amaç: Bu çalışmada antitrombositer ve hemoreolojik ilaç kullanmayan Buerger hastalarında adenozin difosfat (ADP) ve kollajen ile tetiklenen trombosit agregasyon düzeyleri araştırıldı.Çalışma planı: Fontaine III-IV Buerger hastalığı tanısıyla takip edilen ve antiagregan veya hemoreolojik ilaç kullanmayan 10 hastada ve 50 yaşından küçük sağlıklı 10 erkekte (kontrol grubu) ADP ve kollajen ile tetiklenen trombosit agregasyon değerleri, Chrono-log platelet agregometre cihazında ADP ve kollajen Chrono-log kiti kullanılarak ölçüldü.Bulgular: Buerger grubunda ADP ile tetiklenen agregasyonda ortalama değer %78.7±9.7, kontrol grubunda ise %81.5±3.5 bulundu (p>0.05). Kollajen ile tetiklenen trombosit agregasyonunda Buerger grubunda ortalama değer %90.5±10.0, kontrol grubunda %88.5±2.3 idi (p>0.05).Sonuç: Bulgularımız, Buerger hastalarında agregasyona eğilim olmadığını göstermektedir.

🔖

Cite This Article

BOZKURT, A. K., DEMİRBAŞ, M. Y., GÜLSEVER, M. (2022). Comparison of ADP-and collagen-induced platelet aggregation responses between patients with Buerger's disease and healthy individuals. Türk Göğüs Kalp Damar Cerrahisi Dergisi, Cilt: 17 - Sayı: 2, 106–109. https://ajindex.com/articles/424997

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Olin JW. Thromboangiitis obliterans (Buerger’s disease). In: Rutherford RB, editor. Vascular surgery. 6th ed. Vol. 1, Philadelphia: W. B. Saunders; 2005. p. 404-19
  2. Kröger K. Buerger’s disease: What has the last decade taught us? Eur J Intern Med 2006;17:227-34
  3. Vig S, Chitolie A, Sleight S, Bevan D, Dormandy J, Thompson MM, et al. Prevalence and risk of thrombophilia defects in vascular patients. Eur J Vasc Endovasc Surg 2004;28:124-31
  4. Bozkurt AK, Köksal C, Ercan M. The altered hemorheologic parameters in thromboangiitis obliterans: a new insight. Clin Appl Thromb Hemost 2004;10:45 50
  5. Shionoya S. Diagnostic criteria of Buerger’s disease. Int J Cardiol 1998;66 Suppl 1:S243-5
  6. Haimovici H, Mishima Y. Nonatherosclerotic diseases of small arteries. In: Ascher E, Hollier LH, Strandness DE Jr, Towne JB, Calligaro K, Kent KC, et al. editors. Haimovici’s vascular surgery. 5th ed. Boston: Blackwell Publishing; 2004. p. 475-98
  7. Olin JW, Young JR, Graor RA, Ruschhaupt WF, Bartholomew JR. The changing clinical spectrum of thromboangiitis obliterans (Buerger’s disease). Circulation 1990;82(5 Suppl):IV3-8
  8. Puéchal X, Fiessinger JN. Thromboangiitis obliterans or Buerger’s disease: challenges for the rheumatologist. Rheumatology 2007;46:192-9
  9. Avcu F, Akar E, Demirkılıç U, Yılmaz E, Akar N, Yalçın A. The role of prothrombotic mutations in patients with Buerger’s disease. Thromb Res 2000;100:143-7
  10. Brodmann M, Renner W, Stark G, Winkler M, Pabst E, Hofmann C, et al. Prothrombotic risk factors in patients with thrombangitis obliterans. Thromb Res 2000;99:483-6
  11. Choudhury NA, Pietraszek MH, Hachiya T, Baba S, Sakaguchi S, Takada Y, et al. Plasminogen activators and plasminogen activator inhibitor 1 before and after venous occlusion of the upper limb in thromboangiitis obliterans (Buerger’s disease). Thromb Res 1992;66:321-9
  12. Eichhorn J, Sima D, Lindschau C, Turowski A, Schmidt H, Schneider W, et al. Antiendothelial cell antibodies in thromboangiitis obliterans. Am J Med Sci 1998;315:17-23
  13. Makita S, Nakamura M, Murakami H, Komoda K, Kawazoe K, Hiramori K. Impaired endothelium-dependent vasorelaxation in peripheral vasculature of patients with thromboangiitis obliterans (Buerger’s disease). Circulation 1996;94(9 Suppl):II211-5
  14. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007;33 Suppl 1:S1